Dianthus Therapeutics Inc

NASDAQ:DNTH

Dianthus Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. Dianthus Therapeutics, Inc., formerly Magenta Therapeutics, Inc., is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies. The Company’s lead antibody, DNTH103, is engineered with an extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology, enabling less frequent and more convenient self-administered subcutaneous injections. DNTH103 is an investigational, long-acting monoclonal antibody engineered to potently and selectively inhibit the active form of C1s, a clinically validated target in the classical complement pathway. As the classical pathway plays a significant role in disease pathology across a range of neuromuscular disorders, DNTH103 holds the potential to be a pipeline in a product beginning with generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.